Business Description
Zura Bio Ltd
NAICS : 541714
SIC : 2834
ISIN : KYG9TY5A1016
Share Class Description:
ZURA: Ordinary Shares - Class ATotal Employee Number:
40Description
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.25 | |||||
9-Day RSI | 50.63 | |||||
14-Day RSI | 52.99 | |||||
3-1 Month Momentum % | -20.82 | |||||
6-1 Month Momentum % | -33.02 | |||||
12-1 Month Momentum % | 153.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.33 | |||||
Quick Ratio | 19.33 | |||||
Cash Ratio | 19.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -24.93 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -54.6 | |||||
ROA % | -46.17 | |||||
ROIC % | -2009.35 | |||||
ROC (Joel Greenblatt) % | -66795.9 | |||||
ROCE % | -56.02 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.29 | |||||
Price-to-Tangible-Book | 2.28 | |||||
EV-to-EBIT | -3.33 | |||||
EV-to-Forward-EBIT | -2.41 | |||||
EV-to-EBITDA | -3.33 | |||||
EV-to-FCF | -3.73 | |||||
| Price-to-Net-Current-Asset-Value | 2.3 | |||||
| Price-to-Net-Cash | 2.32 | |||||
Earnings Yield (Greenblatt) % | -30.03 | |||||
FCF Yield % | -14.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZURA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zura Bio Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.09 | ||
| Beta | -0.4546 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.59 | ||
| Volatility % | 127.06 | ||
| 14-Day RSI | 52.99 | ||
| 14-Day ATR ($) | 0.403993 | ||
| 20-Day SMA ($) | 5.33825 | ||
| 12-1 Month Momentum % | 153.57 | ||
| 52-Week Range ($) | 1.345 - 7.44 | ||
| Shares Outstanding (Mil) | 95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zura Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zura Bio Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 19 days | ||
| General meeting for 2026 | 2026-06-17 12:00 | 3.52 (-4.48%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.89 (-5.42%) | ||
| Annual report for 2025 | 2026-03-19 | 5.99 (-6.99%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 5.99 (-6.99%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 14:20 | 7.04 (+3.23%) | ||
| Guggenheim Emerging Outlook: Biotech Summit | 2026-02-11 11:00 | 6.44 (+2.22%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 4.63 (+5.23%) | ||
| Guidance call for 2025 | 2025-09-04 14:45 | 2.03 (-0.49%) |
Show
Entries
Zura Bio Ltd Frequently Asked Questions
What is Zura Bio Ltd(ZURA)'s stock price today?
The current price of ZURA is $5.23. The 52 week high of ZURA is $7.44 and 52 week low is $1.35.
When is next earnings date of Zura Bio Ltd(ZURA)?
The next earnings date of Zura Bio Ltd(ZURA) is 2026-08-14 Est..
Does Zura Bio Ltd(ZURA) pay dividends? If so, how much?
Zura Bio Ltd(ZURA) does not pay dividend.
Guru Commentaries on NAS:ZURA
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers